An Open Label, Multi-Center, Dose Escalation/Expansion, Phase 1/1b Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy as monotherapy or in combination with atezolizumab with or without chemotherapy, in Adults with Non-Small Cell Lung Cancer (IMPrinter)

  • Richardson, Gary (Primary Chief Investigator (PCI))
  • Baker, Emma (Project Manager)

Project: Research

Project Details

Effective start/end date14/10/2031/12/24


  • Medical oncology
  • Lung cancer
  • Clinical trial